Kiniksa Pharmaceuticals International, plc Financial Ratios
KNSA / Health Care|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Negative profit margin: -10.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
10.4%
Profit Margin
8.7%
Net Income / Revenue
Asset Turnover
0.89
Revenue / Total Assets
Equity Multiplier
1.35
Total Assets / Equity
Composite: 10.4% (reported: 10.4%)
Profitability
Liquidity
Current Ratio
3.79
Quick Ratio
3.39
Solvency
Interest Coverage
-
Efficiency
Asset Turnover
0.89
Inventory Turnover
1.41
Days Sales Outstanding
8 days
As of FY2025 · SEC 10-K · Updated Jun 30, 2026
Earnings Quality
Accrual Ratio
-11.8%
+0.1pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.